Forskning
Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital
Udgivet

Thalidomide and dexamethasone vs. bortezomib and dexamethasone for melphalan refractory myeloma: a randomized study

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. Heterozygous loss of Srp72 in mice is not associated with major hematological phenotypes

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Addressing the room for improvement in management of acute promyelocytic leukemia

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Risk factors for infections in newly diagnosed Multiple Myeloma patients: A Danish retrospective nationwide cohort study

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. Risk factors for infections in newly diagnosed Multiple Myeloma patients: A Danish retrospective nationwide cohort study

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. The majority of newly diagnosed myeloma patients do not fulfill the inclusion criteria in clinical phase III trials

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Risk factors for blood stream infections in multiple myeloma: A population-based study of 1154 patients in Denmark

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  • Martin Hjorth
  • Øyvind Hjertner
  • Lene Meldgaard Knudsen
  • Nina Gulbrandsen
  • Erik Holmberg
  • Per Trøllund Pedersen
  • Niels Frost Andersen
  • Björn Andréasson
  • Rolf Billström
  • Kristina Carlson
  • Margaretha S Carlsson
  • Max Flogegård
  • Karin Forsberg
  • Peter Gimsing
  • Torbjörn Karlsson
  • Olle Linder
  • Hareth Nahi
  • Annika Othzén
  • Agneta Swedin
  • Nordic Myeloma Study Group (NMSG)
Vis graf over relationer
Thalidomide and bortezomib have been frequently used for second-line therapy in patients with myeloma relapsing after or refractory to initial melphalan-based treatment, but no randomized trials have been published comparing these two treatment alternatives.
OriginalsprogEngelsk
TidsskriftEuropean Journal of Haematology
Vol/bind88
Udgave nummer6
Sider (fra-til)485-96
Antal sider12
ISSN0902-4441
DOI
StatusUdgivet - 2012

ID: 36546814